Physician profile
Bashar S Saikaly
NPI 1700880390
$9,010.03
in general payments reported to CMS, 2019-2025
42 companies · $940 in 2025
The $940 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $1,390 · 2021: $1,352 · 2022: $1,537 · 2023: $1,416 · 2024: $945 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.83 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $918.62 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $903.27 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $846.69 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $734.78 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $734.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $541.67 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.07 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $392.50 | 2020-2025 | |
| Amarin Pharma, INC. | $340.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $324.88 | 2022-2025 | Verquvo, Winrevair |
| Abbott Laboratories | $306.96 | 2019-2023 | Mitraclip |
| Sanofi-Aventis U.S. LLC | $306.07 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $238.13 | 2019-2023 | Camzyos |
| Esperion Therapeutics, INC. | $199.47 | 2020-2024 | Nexletol |
| United Therapeutics Corporation | $183.86 | 2023-2025 | Tyvaso, Tyvaso |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $148.59 | 2020-2022 | |
| Philips North America LLC | $142.52 | 2020-2023 | |
| Boston Scientific Corporation | $139.47 | 2019-2025 | Watchman Flx |
| Abiomed | $129.73 | 2024 | Impella |
| Smith+Nephew, INC. | $126.50 | 2022 | |
| Cardiovascular Systems INC. | $89.33 | 2022 | |
| Baxter Healthcare | $88.83 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.40 | 2019-2021 | |
| Novo Nordisk INC | $76.91 | 2021-2024 | Wegovy |
| Genzyme Corporation | $65.15 | 2022-2023 | |
| Bardy Diagnostics, INC. | $60.66 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $57.71 | 2019 | |
| Chiesi USA, INC. | $37.14 | 2019 | |
| Alnylam Pharmaceuticals INC. | $34.75 | 2020-2025 | Amvuttra |
| Medtronic, INC. | $34.26 | 2021 | |
| Liquidia Technologies, INC. | $32.28 | 2025 | Yutrepia |
| Irhythm Technologies, INC. | $31.84 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Johnson & Johnson Health Care Systems INC. | $30.52 | 2023 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $28.94 | 2025 | Inspire |
| Medtronic Vascular, INC. | $27.46 | 2019 | |
| Celgene Corporation | $20.59 | 2025 | Eliquis |
| Daiichi Sankyo INC. | $19.18 | 2023 | Injectafer |
| Shockwave Medical, INC | $18.93 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.84 | 2024 | |
| Cleerly, INC. | $16.93 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Lilly USA, LLC | $15.75 | 2025 | Mounjaro |
| Kestra Medical Technology Services, INC. | $14.69 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Saikaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.